14. Net result on realization and impairment losses on investments

Net result on realization and impairment losses on investments 1 January - 31 December 2015 1 January - 31 December 2014
Net result on realization of investments (154,692) 380,284
Financial assets measured at fair value through profit or loss – classified as such upon initial recognition, including: 87,723 317,227
- equity instruments 13,369 56,405
- debt instruments 74,354 260,822
Financial assets held for trading, including: (142,136) 97,886
- equity instruments (70,941) (36,469)
- debt instruments (29,515) 34,251
- derivatives (41,680) 100,104
Financial assets available for sale, including: 9,944 21,071
- equity instruments (26,035) 633
- debt instruments 35,979 20,438
Financial assets held to maturity, including: (1,923) 1,371
- debt instruments held to maturity (1,923) 1,371
Loans 7,726 (368)
Receivables, including insurance receivables (51,407) (56,733)
Cash and cash equivalents (378) -
Investment property 6,510 (170)
Result on the sale of PZU Lithuania 165,483 1) -
Effect of consolidation of Alior Bank (236,234)2) -
Impairment losses (68,547) 46,863
Financial assets available for sale, including: - (3,945)
- equity instruments - (3,945)
Loans (51,644) (10,242)
Debt instruments (32,693) (10,144)
Term deposits with credit institutions (947) -
Loans (18,004) (98)
Receivables, including insurance receivables 972 61,0503)
Cash and cash equivalents (1,389) -
Entities measured using the equity method – EMC (16,486) 4) -
Net result on realization and impairment losses on investments (223,239) 427,147

1) Additional information about sale of PZU Lithuania is presented in Note 2.4.1

2) The amount concerns revaluation of Alior Bank shares’ package to fair value as at the moment of acquiring control. Additional information about the settlement of acquisition of Alior Bank SA is presented in Note 2.4.6.1.

3) Including reversal of receivables impairment losses in the amount of PLN 26,275 thousand due to a mortgage to Metro-Projekt Sp. z o.o. described in Note 53.6.

4) Additional information about EMC measurement and impairment tests is presented in Note 34